C-peptide Concentrations in Type 2 Diabetes Treated With Insulin; is it Time to Revise the Treatment of Type 2 Diabetes

Goztepe Training and Research Hospital

Status: Completed

Conditions: Type 2 Diabetes Treated With Insulin

Treatments: Diagnostic Test: C-peptide concentrations

Study type: Observational

Funder types: Other

Identifiers

NCT04005261

C-peptide2019

Details and patient eligibility

About

C-peptide is used to evaluate beta cell reserves. Patients with type 2 diabetes are treated with insulin for different indications. Other than beta-cell insufficiency and organ failures, insulin treatment is needed for a specified period. The investigators want to evaluate beta cell reserves in patients with type 2 diabetes treated with insulin for at least six months to see if that is the case. The investigators also want to compare the characteristics of these patients according to their beta cell reserves.

Full description

In patients with type 2 diabetes, initiation of insulin therapy is indicated in several conditions such as severe insulin resistance, acute metabolic decompensations, surgery, pregnancy, and progression of diabetic complications, and also when glycemic control cannot be achieved with effective lifestyle regulation and non-insulin antidiabetic medications. Some of these indications are transient, and patients should be reassessed to choose the appropriate treatment options. Clinical inertia is one of the new topics expressed in the recent diabetes guidelines. The investigators aimed to investigate the beta cell reserves of the patients with type 2 diabetes who are treated with insulin, to see if they have insufficient insulin secretion and if not, to compare their characteristics.

Enrollment: 249 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with type 2 diabetes who had been treated with insulin as a monotherapy or as a component of combination therapy for at least 6 months.

Exclusion criteria

• Diagnosis of other types of diabetes,
• end-stage renal failure,
• history of renal transplantation,
• diabetic acute metabolic decompensation,
• decompensated heart failure,
• advanced liver disease,
• pregnancy,
• acute or chronic pancreatitis,
• pancreatic carcinoma,
• acute infections,
• use of medications that might affect glucose regulation (e.g. corticosteroids)

Trial design

249 participants in 1 patient group

patients with type 2 diabetes treated with insulin

Description:

Patients with type 2 diabetes who have been using insulin for at least six months. They should be older than 18 years The patients should be presented to the Diabetes Outpatient Clinics of Istanbul Medeniyet University Goztepe Training and Research Hospital

Treatment:

Diagnostic Test: C-peptide concentrations